Publication-grade Systematic Literature Reviews (SLR), quantitative Meta-Analyses, and high-impact peer-reviewed manuscripts conforming to PRISMA, Cochrane, and ICMJE guidelines.
Publishing in top-tier medical journals (Q1/Q2 impact factor) and supporting Health Technology Assessments (HTA) requires more than raw data; it demands immaculate research methodology, reproducible literature synthesis, and strict adherence to international publication ethics (ICMJE, GPP4, and COPE).
Kensai Health provides comprehensive evidence synthesis and medical publication services backed by decades of biopharma, CRO, and academic research rigor. Our senior evidence synthesis specialists and medical writers support biopharma sponsors, academic consortia, and clinical investigators from initial protocol conceptualization through peer-review acceptance.
We synthesize vast clinical datasets into authoritative systematic reviews, quantitative meta-analyses, and compelling trial manuscripts that withstand intense scientific scrutiny.
Every systematic review and manuscript adheres strictly to PRISMA 2020 reporting criteria, PROSPERO registration standards, and ICMJE authorship guidelines.
Complete manuscript authoring and editing for primary clinical trial results, retrospective cohort studies, and secondary post-hoc analyses. We ensure adherence to target journal Instructions for Authors, ICMJE criteria, and EQUATOR guidelines (CONSORT, STROBE).
Exhaustive, reproducible systematic reviews conforming to PRISMA 2020 guidelines and Cochrane Handbook methodologies. We build sensitive database search algorithms across PubMed, Embase, Scopus, Web of Science, and Cochrane Central.
Pooling trial data across published studies to evaluate overall treatment effect sizes, odds ratios, hazard ratios, and relative risks. We construct publication-ready forest plots and funnel plots to assess publication bias.
Quantitative mapping of clinical trial landscapes, emerging therapeutic trends, co-citation networks, and institutional collaboration patterns using specialized bibliometric analytical tools (VOSviewer, Bibliometrix).
Generating targeted clinical evidence syntheses to support Health Economics and Outcomes Research (HEOR), value dossiers, comparative effectiveness evaluations, and payer submissions.
Managing rigorous journal peer-review feedback. We assist authors and steering committees in drafting detailed, respectful, and point-by-point rebuttal letters and revising manuscripts to secure final acceptance.
Demonstrated scholarly authority across digital therapeutics, clinical trials, and medical communication standards.
BMJ Innovations. 2026;12(2):110-118.
Comprehensive peer-reviewed synthesis of digital therapeutics in clinical practice, exploring regulatory frameworks, adoption enablers, and clinical glycemic efficacy.
Handbook on Artificial Intelligence and the Circular Economy. 2026.
Book chapter synthesizing AI applications in sustainable healthcare ecosystems, clinical data governance, and technology adoption frameworks.
Proc Singapore Healthc. 2025;34.
Quantitative bibliometric mapping of clinical trials and global research networks investigating digital therapeutic technologies over a 20-year horizon.
BMC Pulm Med 2026;26:218.
Randomized, double-blind, placebo-controlled Phase 2 trial investigating MN-166 in hospitalized patients with acute respiratory failure.
